Methamphetamine Addiction. Other stimulant abuse
Conditions
Interventions
Intervention 1: Intervention group: Participants receive either 10 mg melatonin (2 melatonin capsules, 5 mg each)once a day 1 hour before bedtime for 4 weeks. Intervention 2: Control group: Particip
Sponsors
Shahroud University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: have a methamphetamine use history longer than 12 months; Male No history of severe Neurological disease No history of severe Head Trauma Do not take psychiatric drugs now
Exclusion criteria
Exclusion criteria: Having severe psychological illness Having blood diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of percentage of circulating stem cells in the blood by measuring CD + 34 and CD45 markers. Timepoint: Pre and Post Treatment. Method of measurement: Flow cytometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep Quality. Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Pittsburgh Sleep Quality Index.;Evaluation of patients' depression. Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Beck Depression Inventory.;Evaluation of patients' anxiety. Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Beck Anxiety Inventory.;Brain-derived neurotrophic factor (BDNF). Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Enzyme-linked Immunosorbent Assay (ELISA) kites.;Glial fibrillary acidic protein (GFAP). Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Enzyme-linked Immunosorbent Assay (ELISA) kites.;Measures brain activity by Functional magnetic resonance imaging(fMRI). Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Using Functional magnetic resonance imaging(fMRI).;Anatomical study of white matter fibers. Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Using Diffusion tensor imaging (DTI).;Investigating changes in Cognitive and functional brain factors such as memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Timepoint: Pre and Post Treatment (beginning of the study and after 28 days of melatonin treatment). Method of measurement: Using the Cambridge Neuropsychological Test Automated Battery(CANTAB). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli reza Azizi
Shahroud University of Medical Sciences
Outcome results
None listed